XML 28 R18.htm IDEA: XBRL DOCUMENT v3.25.1
SUBSEQUENT EVENTS
3 Months Ended
Mar. 31, 2025
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
Capsid Delivery License Agreement with Eli Lilly and Company
On April 3, 2025, the Company entered into a global capsid delivery license agreement (“the Lilly Agreement”), with Eli Lilly and Company (“Lilly”), to develop intravenously administered genomic medicines to treat certain diseases of the CNS. Under the Lilly Agreement, the Company granted a worldwide exclusive license to Lilly to utilize its proprietary, neurotropic adeno-associated virus capsid, STAC-BBB, for one target, with the rights for Lilly to add up to four additional targets after paying additional licensed target fees.
Under the Lilly Agreement, the Company has received an $18.0 million upfront license payment. In addition, the Company is eligible to earn up to $1.4 billion in additional licensed target fees and milestone payments across the five potential CNS disease targets under the Lilly Agreement, as well as tiered royalties on the potential net sales of any resulting products, subject to certain specified reductions.
At-the-Market Offering Program
Subsequent to March 31, 2025, the Company sold 7,090,385 shares of its common stock under the Open Market Sale Agreement℠ with Jefferies, for net proceeds of approximately $5.1 million.